News stories about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat negative this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of -0.09 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.7184342627938 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) opened at $138.75 on Monday. The firm has a market capitalization of $1,970.00, a P/E ratio of -56.40 and a beta of 1.32. Madrigal Pharmaceuticals has a 1-year low of $13.09 and a 1-year high of $154.75.
A number of equities research analysts have weighed in on MDGL shares. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright lifted their target price on Madrigal Pharmaceuticals from $105.00 to $156.00 and gave the stock a “buy” rating in a report on Tuesday, January 30th. Roth Capital lifted their target price on Madrigal Pharmaceuticals from $82.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, December 11th. BidaskClub upgraded Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Finally, JMP Securities lifted their target price on Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $154.20.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.